MCID: RYN001
MIFTS: 49

Raynaud Disease

Categories: Blood diseases, Cardiovascular diseases, Rare diseases, Skin diseases

Aliases & Classifications for Raynaud Disease

MalaCards integrated aliases for Raynaud Disease:

Name: Raynaud Disease 56 12 43 15 17 71
Raynaud's Disease 12 42
Raynaud Syndrome 36 32
Secondary Raynaud's Phenomenon 71
Cold Fingers, Hereditary 56
Raynaud's Syndrome 12
Raynaud Phenomenon 71
Raynauds Syndrome 54

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
raynaud disease:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:10300
OMIM 56 179600
KEGG 36 H01620
MeSH 43 D011928
SNOMED-CT 67 22954002
ICD10 32 I73.0
MedGen 41 C0034734
SNOMED-CT via HPO 68 263681008 266261006
UMLS 71 C0034734 C0034735 C1282916

Summaries for Raynaud Disease

MedlinePlus : 42 Raynaud's disease is a rare disorder of the blood vessels, usually in the fingers and toes. It causes the blood vessels to narrow when you are cold or feeling stressed. When this happens, blood can't get to the surface of the skin and the affected areas turn white and blue. When the blood flow returns, the skin turns red and throbs or tingles. In severe cases, loss of blood flow can cause sores or tissue death. Primary Raynaud's happens on its own. The cause is unknown. There is also secondary Raynaud's, which is caused by injuries, other diseases, or certain medicines. People in colder climates are more likely to develop Raynaud's. It is also more common in women, people with a family history, and those over age 30. Treatment for Raynaud's may include drugs to keep the blood vessels open. There are also simple things you can do yourself, such as Soaking hands in warm water at the first sign of an attack Keeping your hands and feet warm in cold weather Avoiding triggers, such as certain medicines and stress NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Raynaud Disease, also known as raynaud's disease, is related to raynaud phenomenon and scleroderma, familial progressive, and has symptoms including nausea and vomiting, constipation and fatigue. An important gene associated with Raynaud Disease is CENPB (Centromere Protein B), and among its related pathways/superpathways are Oxytocin signaling pathway and Renin secretion. The drugs Cilostazol and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include heart, skin and lung, and related phenotypes are abnormality of the skeletal system and raynaud phenomenon

KEGG : 36 Raynaud syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. Although the underlying pathophysiological mechanism is unclear, alterations in activity of the peripheral adrenoceptor have been implicated, specifically an enhanced smooth muscle contraction due to overexpression or hyperactivity of postsynaptic alpha 2 receptors. RS can occur as an isolated entity, historically referred to as Raynaud disease or now primary RS, or in association with other conditions, most frequently the connective tissue diseases (eg, scleroderma [DS:H01492], systemic lupus erythematosus [DS:H00080], rheumatoid arthritis [DS:H00630], and Sjogren's syndrome [DS:H01502]), often referred to as Raynaud phenomenon or secondary RS. The diagnosis is mainly clinical, based on patient descriptions of skin changes. Therapy has been focused on the use of general vasodilation strategies.

Wikipedia : 74 Raynaud syndrome, also known as Raynaud's phenomenon, is a medical condition in which spasm of arteries... more...

More information from OMIM: 179600

Related Diseases for Raynaud Disease

Diseases related to Raynaud Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 355)
# Related Disease Score Top Affiliating Genes
1 raynaud phenomenon 32.7 PDE5A EDN1 ADRA2C
2 scleroderma, familial progressive 31.1 TOP1 EDN1 CENPB
3 purpura 30.4 CRP CD40LG ACE
4 angina pectoris 30.3 EDN1 CRP ACE
5 peripheral artery disease 30.2 EDN1 CRP ACE
6 intermittent claudication 30.2 CRP CD40LG ACE
7 late congenital syphilis 30.1 CRP CD40LG
8 parotitis 30.0 TRIM21 CRP CD40LG
9 atherosclerosis susceptibility 30.0 EDN1 CRP AGTR1 ACE
10 syphilis 29.9 CRP CD40LG ACE
11 pericarditis 29.9 CRP CD40LG ACE
12 pulmonary edema 29.8 EDN1 CRP AGTR1 ACE
13 autoimmune disease 29.8 TRIM21 IL1R1 CRP CENPB CD40LG
14 telangiectasis 29.8 TRIM21 TOP1 SNRNP70 CENPB CENPA
15 fibromyalgia 29.7 HTR3A CRP CALCA
16 systemic scleroderma 29.7 TRIM21 TOP1 SNRNP70 EDN1 CRP CENPB
17 complex regional pain syndrome 29.7 IL1R1 EDN1 CALCA ACE
18 fibromuscular dysplasia 29.6 AGTR1 ACE
19 coronary artery vasospasm 29.5 EDN1 CRP ADRA2C ACE
20 peripheral nervous system disease 29.4 CRP CD40LG CALCA ACE
21 polyneuropathy 29.4 CRP CD40LG CALCA ACE
22 arteriosclerosis 29.3 EDNRA EDN1 CRP ACE
23 crest syndrome 29.2 TOP1 SNRNP70 CENPB CENPA CD40LG
24 diffuse scleroderma 29.2 TRIM21 TOP1 SNRNP70 EDN1 CENPB ACE
25 migraine with aura 29.2 EDNRA EDN1 CALCA ACE
26 hellp syndrome 29.1 EDN1 CRP CD40LG
27 diabetes mellitus 29.0 PDE5A IL1R1 EDN1 CRP CD40LG AGTR1
28 systemic lupus erythematosus 28.7 TRIM21 SNRNP70 IL1R1 CRP CENPB CD40LG
29 collagen disease 28.7 TRIM21 TOP1 SNRNP70 EDN1 CRP CENPB
30 pulmonary hypertension 28.4 PDE5A EDNRA EDN1 CRP CALCA AGTR1
31 rheumatic disease 28.4 TRIM21 TOP1 IL1R1 CRP CENPB CENPA
32 migraine with or without aura 1 27.8 PDE5A HTR3A EDNRA EDN1 CRP CD40LG
33 connective tissue disease 27.6 TOP1 SNRNP70 EDNRA EDN1 CRP CENPB
34 hypertension, essential 27.0 PDE5A EDNRA EDN1 CRP CD40LG CALCA
35 reynolds syndrome 11.5
36 cryopyrin-associated periodic syndrome 10.5 IL1R1 CRP
37 chronic thromboembolic pulmonary hypertension 10.5 EDN1 CRP
38 mediastinum teratoma 10.5 CRP ACE
39 acute dacryoadenitis 10.5 CRP ACE
40 subacute cutaneous lupus erythematosus 10.5 TRIM21 ACE
41 alzheimer disease 5 10.4 AGTR1 ACE
42 hyperglobulinemic purpura 10.4 TRIM21 CD40LG
43 facial hemiatrophy 10.4 SNRNP70 CRP
44 conjunctival vascular disease 10.4 TRIM21 TOP1
45 posterior urethral valves 10.4 AGTR1 ACE
46 multiple cranial nerve palsy 10.4 CRP ACE
47 anterior scleritis 10.4 CRP ACE
48 posterior scleritis 10.4 CRP ACE
49 tolosa-hunt syndrome 10.4 CRP ACE
50 orbital plasma cell granuloma 10.4 CRP CD40LG

Graphical network of the top 20 diseases related to Raynaud Disease:



Diseases related to Raynaud Disease

Symptoms & Phenotypes for Raynaud Disease

Human phenotypes related to Raynaud Disease:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the skeletal system 31 HP:0000924
2 raynaud phenomenon 31 HP:0030880

Symptoms via clinical synopsis from OMIM:

56
Limbs:
intermittent attacks of numb and white fingers

Clinical features from OMIM:

179600

UMLS symptoms related to Raynaud Disease:


nausea and vomiting, constipation, fatigue, fever, angina pectoris, abdominal pain, edema, pruritus, chest pain, pain, headache, diarrhea, syncope, halitosis, chronic pain, sciatica, icterus, coughing, vertigo/dizziness, symptoms, dyspepsia, heartburn, gastrointestinal gas, pelvic pain, cold intolerance, joint or joint related complaint

MGI Mouse Phenotypes related to Raynaud Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.23 ACE AGTR1 CD40LG EDN1 EDNRA HTR3A

Drugs & Therapeutics for Raynaud Disease

Drugs for Raynaud Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
5 Phosphodiesterase Inhibitors Phase 4
6 Phosphodiesterase 3 Inhibitors Phase 4
7 Platelet Aggregation Inhibitors Phase 4
8 abobotulinumtoxinA Phase 4
9 Pharmaceutical Solutions Phase 4
10 Acetylcholine Release Inhibitors Phase 4
11 Neuromuscular Agents Phase 4
12 Cholinergic Agents Phase 4
13 Botulinum Toxins Phase 4
14 Botulinum Toxins, Type A Phase 4
15 Anesthetics, Local Phase 4
16 Anti-Arrhythmia Agents Phase 4
17 Anesthetics Phase 4
18 Analgesics, Non-Narcotic Phase 4
19 Sodium Channel Blockers Phase 4
20 Lidocaine, Prilocaine Drug Combination Phase 4
21 Central Nervous System Depressants Phase 4
22 Analgesics Phase 4
23 Diuretics, Potassium Sparing Phase 4
24 Fibrinolytic Agents Phase 4
25 Anti-Inflammatory Agents Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Antipyretics Phase 4
28 Cyclooxygenase Inhibitors Phase 4
29 Antirheumatic Agents Phase 4
30
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
31
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
32
Udenafil Approved, Investigational Phase 2, Phase 3 268203-93-6 6918523
33
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
34
Nifedipine Approved Phase 3 21829-25-4 4485
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
36
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
37
Pseudoephedrine Approved Phase 3 90-82-4 7028
38
Ephedrine Approved Phase 3 299-42-3 9294
39
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
40
Ondansetron Approved Phase 3 99614-02-5 4595
41
Diclofenac Approved, Vet_approved Phase 3 15307-86-5 3033
42
Atropine Approved, Vet_approved Phase 3 5908-99-6, 51-55-8 174174
43
Norepinephrine Approved Phase 2, Phase 3 51-41-2 439260
44
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
45
Iloprost Approved, Investigational Phase 3 78919-13-8 6443959
46
Nitrous oxide Approved, Vet_approved Phase 3 10024-97-2 948
47
Prilocaine Approved Phase 3 721-50-6 4906
48
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
49
Terlipressin Approved, Investigational Phase 2, Phase 3 14636-12-5 72081
50
Racepinephrine Approved Phase 2, Phase 3 329-65-7 838

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
2 Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048763 Phase 4 Pletal
3 The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon, a Double-Blind Randomized Placebo-Controlled Trial Recruiting NCT03639766 Phase 4 AbobotulinumtoxinA
4 Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Patients With Systemic Sclerosis Recruiting NCT03558854 Phase 4 Acetylsalicylic acid;Placebo oral capsule
5 Anesthetic Ointment vs Local Injectable Anesthetic in Trans-radial Cardiac Catheterization: The RAOLA Study Recruiting NCT03072394 Phase 4 Local anesthetic;local anaesthetic injection
6 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion, in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Peritonitis. Recruiting NCT03771170 Phase 4 Rheosorbilact®;Ringer lactate
7 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion, in Comparison With Ringer's Lactate, Solution for Infusion, in a Complex Therapy of Sepsis. Recruiting NCT03764085 Phase 4 Rheosorbilact®;Ringer lactate
8 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion ("Yuria-Pharm"), in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Pneumonia. Recruiting NCT03824457 Phase 4 Rheosorbilact®;Ringer lactate
9 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion ("Yuria-Pharm"), in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Burns Recruiting NCT04152096 Phase 4 Rheosorbilact®;Ringer lactate
10 A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
11 A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
12 Double-blind, Placebo-controlled Cross-over Study to Investigate the Effects of the Phosphodiesterase 5-inhibitor Vardenafil on Periphery Blood Flow and Clinical Symptoms of Patients With Raynaud's Syndrome Completed NCT01291199 Phase 2, Phase 3 vardenafil;Placebo
13 Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial Completed NCT01280266 Phase 2, Phase 3 Udenafil or Amlodipine
14 Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
15 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
16 A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
17 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
18 Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
19 Raynaud's Treatment Study (RTS) Completed NCT00000530 Phase 3 nifedipine
20 Efficacy and Safety of "as Required" Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP) Completed NCT02050360 Phase 2, Phase 3 Sildenafil 40 mg;Sildenafil 80 mg;Placebo
21 A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon Completed NCT00351117 Phase 3 St. John's Wort;Lactose
22 Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud’s Phenomenon Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
23 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study Completed NCT01117298 Phase 3 Tadalafil;Placebo
24 Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
25 Efficacy, Tolerability and Biology of a Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
26 Effects of Addition of Systemic Tramadol or Adjunct Tramadol to Lidocaine Used for Intravenous Regional Anesthesia in Patients Undergoing Hand Surgery Completed NCT02658721 Phase 3 Lidocaine;lidocaine+adjunct tramadol;lidocaine+systemic tramadol;Fentanyl;Atropine;Midazolam;Diclofenac sodium;Ephedrine;Ondansetron
27 Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Study to Assess Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis Recruiting NCT03717961 Phase 3 BOTOX® solution;Placebo group
28 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study) Recruiting NCT04040322 Phase 3 Placebo IV infusion;Iloprost Injection, for intravenous use
29 Terlipressin Alone Versus the Standard Therapy With Catecholamines for Hepatic Patients With Septic Shock- Prospective Single Center Randomized Controlled Study. Recruiting NCT03608514 Phase 2, Phase 3 Experimental
30 Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial Recruiting NCT02413268 Phase 3 Nitroglycerin
31 Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine Terminated NCT02374320 Phase 2, Phase 3 liposomal bupivacaine
32 Safety and Efficacy Study of Pl-vegf165 to Treat Secondary Raynaud's Phenomenon Caused by Systemic Scleroderma Unknown status NCT02356809 Phase 1, Phase 2 Neovasculgen
33 A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma) Completed NCT02228850 Phase 2 Alprostadil
34 A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon Completed NCT01090492 Phase 2 PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791
35 A 28-Day Randomized, Double-Blind, Placebo-Controlled Clinical Trial and 5-Year Prospective Outcomes Study: A Two-Part Study of BOTOX® Therapy for Ischemic Digits Completed NCT01309802 Phase 2 onabotulinum toxin type-A
36 A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease. Completed NCT00528242 Phase 2 SLx-2101;Placebo
37 Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00378521 Phase 2 MQX-503
38 Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon Completed NCT00251238 Phase 2 Ginkgo biloba extract EGb 761
39 Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00480753 Phase 2 Nitroglycerin
40 Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial of the Efficacy and Safety of IC351 in Female Patients With Raynaud Phenomenon and Female Sexual Dysfunction Secondary to Systemic Sclerosis Completed NCT00707187 Phase 2 Cialis
41 Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP) Completed NCT01926847 Phase 2 Riociguat (Adempas, BAY63-2521);Placebo
42 Assessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers. Completed NCT02801305 Phase 2 Diltiazem Gel 2%;Nitroglycerin Ointment 2%;Vaseline
43 A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02260557 Phase 2 Selexipag;Placebo
44 A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine, Vascana®, Versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects With Raynaud's Phenomenon (RP) Secondary to Connective Tissue Disease Completed NCT02688270 Phase 2 Vascana (0.9% nitroglycerin cream);Vehicle (placebo)
45 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis Active, not recruiting NCT03867097 Phase 2 Placebo IV infusion;Iloprost Injection, for intravenous use
46 The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis Active, not recruiting NCT02370784 Phase 2 atorvastatin;Placebo
47 Phase IIa Study of the Efficacy of ORM-12471 for Prevention of Cold-induced Vasospasm: a Randomised, Double-blind, Placebo-controlled, Single Centre Crossover Study in Patients With Raynaud's Phenomenon Secondary to Systemic Sclerosis Terminated NCT01315899 Phase 2 ORM-12471 30mg;ORM-12471;placebo
48 A Phase I Trial of the Pharmacodynamic Dose Response to Topical Trinitrate in Patients With Raynaud's Phenomenon Completed NCT00700518 Phase 1 placebo cream;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate
49 MXQ-503 Applied To The Hand Vs. Nitroglycerin Ointment 2%, USP, Applied To The Chest: A Pharmacokinetic Comparison In Normal Subjects Completed NCT00841594 Phase 1 nitroglycerin 0.9 % (MXQ-503);Nitroglycerin ointment 2%, USP
50 Monocenter, IIT, Open Controlled and Prospectiv Study to Define the Prognostic Influence of Light Rheography Measurement of Patients With Secundary Raynaud Syndrome With Ulcers at Fingertips Throughout the Medicinal Therapy Unknown status NCT01378845 Tracleer;Prostavasin

Search NIH Clinical Center for Raynaud Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Captopril
Isoxsuprine
Isoxsuprine Hydrochloride
Papaverine
Papaverine Hydrochloride
Prazosin
Prazosin hydrochloride
Tolazoline
Tolazoline Hydrochloride

Cochrane evidence based reviews: raynaud disease

Genetic Tests for Raynaud Disease

Anatomical Context for Raynaud Disease

MalaCards organs/tissues related to Raynaud Disease:

40
Heart, Skin, Lung, Smooth Muscle, Testes, Endothelial, Spinal Cord

Publications for Raynaud Disease

Articles related to Raynaud Disease:

(show top 50) (show all 1006)
# Title Authors PMID Year
1
Botulinum Toxin in the Long-Term Treatment of Refractory Raynaud’s Phenomenon 42
31524993 2019
2
Nailfold Video Capillaroscopy: Beyond Systemic Sclerosis. 42
31507130 2019
3
The relationship between Raynaud's phenomenon and Helicobacter pylori. 42
31747762 2019
4
Renin-angiotensin system mediators and Raynaud's phenomenon. 54 61
17003081 2006
5
Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: the role of endothelin. 54 61
10334963 1999
6
Cutaneous responses to endothelin-1 and histamine in patients with vibration white finger. 54 61
9457906 1998
7
Functional studies in small arteries do not support a primary role for endothelin in the pathogenesis of Raynaud's disease. 54 61
9595516 1998
8
Highlights on endothelins: a review. 54 61
9441724 1997
9
Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. 54 61
8129780 1994
10
[New therapeutic possibilities with drugs affecting serotonin receptors]. 54 61
1509427 1992
11
Rhabdomyolysis as an initial presentation of systemic lupus erythematosus: a case report. 61
31703554 2019
12
Computed Tomography (CT)-Guided Percutaneous Thoracic Sympathetic Chain Radiofrequency Thermocoagulation for Raynaud Disease. 61
31576813 2019
13
[Antisynthetase syndromes]. 61
31346706 2019
14
Immunologic adverse reactions of β-blockers and the skin. 61
31384329 2019
15
Cyanosis With Dysautonomia Mimics Raynaud Disease. 61
31389817 2019
16
Primary Raynaud Disease. 61
31135869 2019
17
Botulinum Toxin Injection for Lower Face and Oral Cavity Raynaud Phenomenon After Mandibulectomy, Free Fibula Reconstruction, and Radiation Therapy. 61
30260839 2019
18
An Atypical Presentation of Raynaud's Disease. 61
30856621 2019
19
A Literature Based Discovery Visualization System with Hierarchical Clustering and Linking Set Associations. 61
31259013 2019
20
Systemic Sclerosis and Serum Content of Transforming Growth Factor. 61
30758773 2019
21
Acupuncture Point "Hegu" (LI4) Is Close to the Vascular Branch from the Superficial Branch of the Radial Nerve. 61
31341499 2019
22
The importance of perfusion index monitoring in evaluating the efficacy of stellate ganglion blockage treatment in Raynaud's disease. 61
29350104 2018
23
New onset acute pulmonary edema after methylergonovine given during cesarean delivery of a patient with undiagnosed Raynaud's disease. 61
30392649 2018
24
Anatomical Variation of the Radial Artery Associated With Clinically Significant Ischemia. 61
29602651 2018
25
Vascular branches from cutaneous nerve of the forearm and hand: Application to better understanding raynaud's disease. 61
28960445 2018
26
Effects of Endoscopic Thoracic Sympathectomy on Raynaud's Disease. 61
29327980 2018
27
[Quality of life of patients with Raynaud's disease]. 61
29658285 2018
28
Agreement between ccNexfin CO-trek cardiac output and intermittent cold-bolus pulmonary thermodilution in a prospective multicenter study. 61
29239149 2018
29
[Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients]. 61
29425538 2018
30
Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. 61
29044769 2018
31
Hyperbaric oxygen therapy for digital ulcers due to Raynaud's disease. 61
30397635 2018
32
Calcinosis Cutis: WOC Nurse Management. 61
29300294 2018
33
Surgical Interventions for Organ and Limb Ischemia Associated With Primary and Secondary Antiphospholipid Antibody Syndrome With Arterial Involvement. 61
28920529 2017
34
Classification of Japanese patients with mild/early systemic sclerosis (SSc) by the 2013 ACR/EULAR classification criteria for SSc. 61
27830961 2017
35
Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease. 61
27682649 2017
36
[Hematopoietic stem cells transplant in patients with common variable immunodeficiency. Is a therapeutic option?] 61
28188718 2017
37
Acute Vision Loss Following Endoscopic Sinus Surgery. 61
28286685 2017
38
Comparison of Transradial vs Transfemoral Access for Aortoiliac and Femoropopliteal Interventions: A Single-Center Experience. 61
27558461 2016
39
Thoracic sympathectomy for upper extremity ischemia. 61
27175977 2016
40
Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers. 61
27465880 2016
41
Endoscopic thoracic sympathectomy for upper limb ischemia. A 16 year follow-up in a single center. 61
25900032 2016
42
Raynaud's Syndrome: a neglected disease. 61
25673314 2016
43
A Review of Raynaud's Disease. 61
27311222 2016
44
Severe Primary Raynaud's Disease Treated with Rituximab. 61
27651971 2016
45
A Case Report of Neurosarcoidosis Presenting as a Lymphoma Mimic. 61
27800198 2016
46
Angioplasty of forearm arteries as a finger salvage procedure for patient with end-stage renal failure. 61
27143949 2016
47
Synergistic Effect of Ferulic Acid and Z-Ligustilide, Major Components of A. sinensis, on Regulating Cold-Sensing Protein TRPM8 and TPRA1 In Vitro. 61
27413384 2016
48
Primary care assessment of capillaroscopy abnormalities in patients with Raynaud's phenomenon. 61
26400642 2015
49
Two-Step Incision for Periarterial Sympathectomy of the Hand. 61
26618125 2015
50
Acroosteolysis presenting with brachyonychia following exposure to cold. 61
25385354 2015

Variations for Raynaud Disease

Expression for Raynaud Disease

Search GEO for disease gene expression data for Raynaud Disease.

Pathways for Raynaud Disease

Pathways related to Raynaud Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.91 EDNRA EDN1 CALCA AGTR1
2 10.76 EDNRA EDN1 AGTR1 ACE
3 10.66 EDNRA EDN1 CALCA

GO Terms for Raynaud Disease

Cellular components related to Raynaud Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 condensed nuclear chromosome, centromeric region GO:0000780 8.96 CENPB CENPA
2 nuclear pericentric heterochromatin GO:0031618 8.62 CENPB CENPA

Biological processes related to Raynaud Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.72 IL1R1 CRP CD40LG CALCA AGTR1
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.56 EDNRA EDN1 CALCA AGTR1
3 artery smooth muscle contraction GO:0014824 9.43 EDNRA EDN1
4 regulation of glucose transmembrane transport GO:0010827 9.4 EDNRA EDN1
5 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.37 AGTR1 ACE
6 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.33 EDN1 CALCA AGTR1
7 regulation of blood pressure GO:0008217 9.26 EDNRA EDN1 CALCA ACE
8 regulation of vasoconstriction GO:0019229 8.92 EDN1 AGTR1 ADRA2C ACE

Molecular functions related to Raynaud Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bradykinin receptor binding GO:0031711 8.62 AGTR1 ACE

Sources for Raynaud Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....